Overview

NSCLC Exon 20 or HER2-activating Mutations

Status:
Not yet recruiting
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
Phase 2, Open Label, single treatment
Phase:
Phase 2
Details
Lead Sponsor:
Rain Therapeutics, inc